Ata 2013.

Methods	Study design: parallel RCT Study duration: January 2009 to January 2012 Study follow‐up: 3 months
Participants	Country: Turkey Setting: single centre (Istanbul) Inclusion criteria: adults DD kidney transplant recipients Number: treatment group 1 (11); treatment group 2 (10) Mean age ± SD (years): treatment group 1 (43.6 ± 4); treatment group 2 (37 ± 3.8) Sex (M/F): treatment group 1 (3/8); treatment group 2 (4/6) Exclusion criteria: not reported
Interventions	Treatment group 1 ATG modified by CD3 count: 1 mg/kg at time of transplant Continued daily for 10 days with dose as follows as per CD3 count > 150/mL: no adjustment 50 to 150/mL: half dose < 50/mL: dose skipped Treatment group 2 ATG standard dose: 1 mg/kg at time of transplant Continued same dose daily for 10 days Dose skipped if lymphocyte count < 300/mL Maintenance immunosuppression Not specified for either group
Outcomes	ATG dose Side effects Graft function at 3 months Acute rejection Infection Cost (CD3+ analysis + ATG)
Notes	Brief report only Funding source: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported but likely not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not reported but likely not blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	Unclear risk	Brief report only
Other bias	Unclear risk	Funding not reported